EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin

David Healy, Audrey Bahrick, Maarten Bak, Angelo Barbato, Rocco Salvatore Calabrò, Barbara M Chubak, Fiammetta Cosci, Antonei B Csoka, Barbara D'Avanzo, Silvia Diviccaro, Silvia Giatti, Irwin Goldstein und 25 weitere

International Journal of Risk & Safety in Medicine · 22.02.2022 · 33 (1) · 65-76

DOI: 10.3233/jrs-210023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Risk & Safety in Medicine, erschienen am 22.02.2022. Verfasst von David Healy und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Finasteride, Sexual Dysfunction, Physiological. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin. OBJECTIVE: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD). METHODS: The original draft was designed using data from two published case series (Hogan et al., 2014 and Healy et al., 2018), which represent the largest public collections of data on these enduring conditions. It was further developed with the involvement of a multidisciplinary panel of experts. RESULTS: A set of criteria were agreed upon for each of the above conditions. Features of PSSD, PFS and PRSD commonly include decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction. Ancillary non-sexual symptoms vary depending on the specific condition but can include emotional blunting and cognitive impairment. PGAD presents with an almost mirror image of unwanted sensations of genital arousal or irritability in the absence of sexual desire. A new term, post-SSRI asexuality, is introduced to describe a dampening of sexual interest and pleasure resulting from a pre-natal or pre-teen exposure to a serotonin reuptake inhibitor. CONCLUSIONS: These criteria will help in both clinical and research settings. As with all criteria, they will likely need modification in the light of developments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FinasterideSexual Dysfunction, PhysiologicalAdolescentAntidepressive AgentsChildHumansIsotretinoinMaleSelective Serotonin Reuptake Inhibitors

Stichwörter der Autor:innen

Post-SSRI sexual dysfunctionantidepressantsfinasterideisotretinoinselective serotonin reuptake inhibitors

Substanzen

Antidepressive AgentsFinasterideIsotretinoinSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Family Medicine, McMaster University, Hamilton, ON, Canada.
  • University Counseling Service, University of Iowa, Iowa City, IA, USA.
  • Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.
  • FACT, Mondriaan Mental Health, Maastricht/Heerlen, The Netherlands.
  • Unit for Quality of Care and Rights Promotion in Mental Health, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
  • IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy.

Zitieren

APA

Healy, D., Bahrick, A., Bak, M., Barbato, A., Calabrò, R. S., Chubak, B. M., Cosci, F., Csoka, A. B., D'Avanzo, B., Diviccaro, S., Giatti, S., Goldstein, I., Graf, H., Hellstrom, W. J. G., Irwig, M. S., Jannini, E. A., Janssen, P. K. C., Khera, M., Kumar, M. T., …, & Waraich, A. (2022). Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. International Journal of Risk & Safety in Medicine, 33(1), 65-76. https://doi.org/10.3233/jrs-210023

Vancouver

Healy D, Bahrick A, Bak M, Barbato A, Calabrò RS, Chubak BM, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. International Journal of Risk & Safety in Medicine. 2022;33(1):65-76. doi:10.3233/jrs-210023

BibTeX
@article{Healy2022,
  author = {Healy, David and Bahrick, Audrey and Bak, Maarten and Barbato, Angelo and Calabrò, Rocco Salvatore and Chubak, Barbara M and Cosci, Fiammetta and Csoka, Antonei B and D'Avanzo, Barbara and Diviccaro, Silvia and Giatti, Silvia and Goldstein, Irwin and Graf, Heiko and Hellstrom, Wayne J G and Irwig, Michael S and Jannini, Emmanuele A and Janssen, Paddy K C and Khera, Mohit and Kumar, Manoj Therayil and Le Noury, Joanna and Lew-Starowicz, Michał and Linden, David E J and Lüning, Celine and Mangin, Dee and Melcangi, Roberto Cosimo and Rodríguez, Omar Walid Muquebil Ali Al Shaban and Panicker, Jalesh N and Patacchini, Arianna and Pearlman, Amy M and Pukall, Caroline F and Raj, Sanjana and Reisman, Yacov and Rubin, Rachel S and Schreiber, Rudy and Shipko, Stuart and Vašečková, Barbora and Waraich, Ahad},
  title = {Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin},
  journal = {International Journal of Risk & Safety in Medicine},
  year = {2022},
  volume = {33},
  number = {1},
  pages = {65--76},
  doi = {10.3233/jrs-210023}
}
Kostenlos starten →